Henlius Says ASTRIDE Trial Shows Favorable Survival for Serplulimax
Shanghai Henlius Biotech reports that its ASTRIDE trial showed favorable median overall survival for serplulimax versus atezolizumab.
Related stories
Resolute Says Syama Mine Stabilised, Output Expected to Rebound
Resolute Mining executives said its flagship Syama gold mine in Mali has largely stabilised after months of operational disruptions, with production expected to rebound sharply in
M impact | EQUITY | Oct 29, 2026, 02:05 PM UTC
The United States Small-cap Stock Market Index (2000) Hit 5-week High
US Index 2000 increased to 2865.00 Index Points, the highest since September 2026. Over the past 4 weeks, United States Small-cap Stock Market Index (2000) gained 2.38%, and in the
L impact | EQUITY | Oct 29, 2026, 02:04 PM UTC
LKQ Shares Rise Despite Lower Q3 Adjusted Earnings and Revenue
LKQ shares were up over 3% in early Thursday trading despite lower third-quarter adjusted earnings and revenue.
M impact | EQUITY | Oct 29, 2026, 02:03 PM UTC
Fortrea Shares Fall More Than 10% After Q3 Results
Fortrea shares fell more than 10% in early morning trading after the company reported Q3 results.
M impact | EQUITY | Oct 29, 2026, 02:03 PM UTC
Jordan Press and Publishing Q3 revenue 989,360 dinars
M impact | EQUITY | Oct 29, 2026, 02:03 PM UTC
Analysts Raise Price Targets for ICON After Q3 Earnings
Deutsche Bank raised its ICON target to $250 from $200, RBC to $226 from $185, and Truist Securities to $268 from $209. All three firms maintained their existing Buy or Outperform
M impact | EQUITY | Oct 29, 2026, 02:03 PM UTC